Sylwia Sławek-Szmyt, Aleksander Araszkiewicz, Stanisław Jankiewicz, Marek Grygier, Tatiana Mularek-Kubzdela, Maciej Lesiak
PURPOSE: Intermediate-high-risk pulmonary embolism (IHR PE) is a challenging form of embolism obstruction that causes right ventricular (RV) dysfunction. The optimal management of IHR PE has not been established. This single-center prospective, observational study aimed to evaluate the efficacy and safety of complex catheter-directed therapy (CDT) - catheter-directed mechanical aspiration thrombectomy (CDMT) supplemented with catheter-directed thrombolysis (hybrid CDT) in comparison to CDMT alone for IHR PE...
April 2, 2024: Cardiovascular Drugs and Therapy
Saifei Liu, Indy Aj Lawrie, Bibi Rabia, John D Horowitz
No abstract text is available yet for this article.
March 23, 2024: Cardiovascular Drugs and Therapy
Vincenzo Russo, Eleonora Caiazza, Fiorella Chiara Delle Femine, Enrica Pezzullo, Sara Sarpa, Antonio Ianniciello, Caturano Alfredo, Antonello D'Andrea, Paolo Golino, Gerardo Nigro
BACKGROUND: The withdrawal timing of direct oral anticoagulants (DOACs) among patients in need of elective invasive surgery is based on DOAC pharmacokinetics in order to perform the procedure out of the DOAC peak plasma concentration. We aimed to investigate the prevalence and predictors of plasma levels of DOACs out of trough range in patients with atrial fibrillation (AF) in need of elective cardiac procedure. MATERIALS AND METHODS: We evaluated all consecutive AF patients on DOAC therapy in need of elective cardiac procedure, admitted to our division from January 2022 to March 2022...
March 20, 2024: Cardiovascular Drugs and Therapy
András Nagy, Denise Börzsei, Alexandra Hoffmann, Szilvia Török, Médea Veszelka, Nikoletta Almási, Csaba Varga, Renáta Szabó
While oncotherapy has made rapid progress in recent years, side effects of anti-cancer drugs and treatments have also come to the fore. These side effects include cardiotoxicity, which can cause irreversible cardiac damages with long-term morbidity and mortality. Despite the continuous in-depth research on anti-cancer drugs, an improved knowledge of the underlying mechanisms of cardiotoxicity are necessary for early detection and management of cardiac risk. Although most reviews focus on the cardiotoxic effect of a specific individual chemotherapeutic agent, the aim of our review is to provide comprehensive insight into various agents that induced cardiotoxicity and their underlying mechanisms...
March 16, 2024: Cardiovascular Drugs and Therapy
Yuan Xue, Shipan Wang, Xuehuan Zhang, Xiaomeng Wang, Yue Shi, Hongjia Zhang, Duanduan Chen, Haiyang Li
OBJECTIVE: This study aims to investigate the clinical manifestations, operative techniques, and outcomes of patients who undergo open repair after thoracic endovascular aortic repair (TEVAR). METHODS: From January 2010 to June 2022, 113 consecutive type A aortic dissection (TAAD) patients underwent secondary open operation after TEVAR at our institution, and the median interval from primary intervention to open surgery was 12 (1.9-48.0) months. We divided the patients into two groups (RTAD (retrograde type A dissection) group, N = 56; PNAD (proximal new aortic dissection) group, N = 57) according to their anatomical features...
March 15, 2024: Cardiovascular Drugs and Therapy
Jonathan Ka-Ming Ho, Hon-Lon Tam, Leona Yuen-Ling Leung
PURPOSE: This systematic review (SR) of SRs evaluates the effectiveness of vasopressin alone or in combination with other drugs in improving the outcomes of cardiac arrest (CA). METHODS: Using a three-step approach, we searched five databases to identify all relevant SRs. Two reviewers independently selected suitable studies, assessed study quality, and extracted relevant data. If an outcome was reported by multiple SRs, a re-meta-analysis was conducted as needed; otherwise, a narrative analysis was performed...
March 12, 2024: Cardiovascular Drugs and Therapy
Jun Gu, Zhi-Hua Han, Chang-Qian Wang, Jun-Feng Zhang
PURPOSE: Even though nirmatrelvir-ritonavir can improve the short-term morbidity and mortality in COVID-19 patients, the effects of this treatment on long-term major adverse cardiovascular events (MACEs), especially myocardial injury, remains undetermined. METHODS: This prospective cohort study identified hospitalized adult patients with COVID-19 between April 19, 2022, and June 9, 2022, amid the omicron wave of the pandemic. Matched nirmatrelvir-ritonavir-treated and non-treated cohorts were formed using the propensity score matching method...
March 11, 2024: Cardiovascular Drugs and Therapy
Robert S Rosenson, Daniel J Rader, Shazia Ali, Poulabi Banerjee, Jennifer McGinniss, Robert Pordy
PURPOSE: Natural selection (Mendelian randomization) studies support a causal relationship between elevated triglyceride-rich lipoproteins (TRLs) and atherosclerotic cardiovascular disease (ASCVD). This post-hoc analysis assessed the efficacy of evinacumab in reducing TRLs in patient cohorts from three separate clinical trials with evinacumab. METHODS: Patients with homozygous familial hypercholesterolemia (HoFH) and low-density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL were enrolled in a phase III trial (R1500-CL-1629; NCT03399786)...
March 6, 2024: Cardiovascular Drugs and Therapy
Xiaodi Zhang, Yi Zhao, Dafen Guo, Mingxian Luo, Qing Zhang, Li Zhang, Dengshen Zhang
BACKGROUND: AMPK is considered an important protein signaling pathway that has been shown to exert prominent cardioprotective effects on the pathophysiological mechanisms of numerous diseases. Following myocardial infarction, severe impairment of cardiac function occurs, leading to complications such as heart failure and arrhythmia. Therefore, protecting the heart and improving cardiac function are important therapeutic goals after myocardial infarction. Currently, there is substantial ongoing research on exercise-centered rehabilitation training, positioning exercise training as a significant nonpharmacological approach for preventing and treating numerous cardiovascular diseases...
March 4, 2024: Cardiovascular Drugs and Therapy
Shichao Wei, Feng Ju, Junshen Xiao, Jiaxue Li, Ting Liu, Zhaoyang Hu
OBJECTIVE: Myocardial ischemia/reperfusion (I/R) injury can cause severe cardiac damage. Aloperine is a quinolizidine alkaloid found in the leaves and seeds of Sophora alopecuroides L. It has been recognized that aloperine has organ-protective properties; however, its role in cardioprotection is poorly characterized. This study aimed to evaluate the cardioprotective effects of aloperine against myocardial I/R injury in vivo. METHODS: Adult male Sprague‒Dawley rats were randomly divided into sham-operated, control, and aloperine groups...
February 28, 2024: Cardiovascular Drugs and Therapy
Sa Liu, Jiaqin Liu, Nan Su, Shanshan Wei, Ning Xie, Xiangyun Li, Suifen Xie, Jian Liu, Bikui Zhang, Wenqun Li, Shengyu Tan
PURPOSE: Doxorubicin (Dox) is clinically limited due to its dose-dependent cardiotoxicity. Andrographolide (Andro) has been confirmed to exert cardiovascular protective activities. This study aimed to investigate protective effects of Andro in Dox-induced cardiotoxicity (DIC). METHODS: The cardiotoxicity models were induced by Dox in vitro and in vivo. The viability and apoptosis of H9c2 cells and the myocardial function of c57BL/6 mice were accessed with and without Andro pretreatment...
February 24, 2024: Cardiovascular Drugs and Therapy
Yating Xu, Di Xia, Shan Deng, Minglu Liang
PURPOSE: Angiogenesis involves in many pathological processes, including tumor metastasis, diabetic retinopathy, and rheumatoid arthritis. Therefore, identifying therapeutic drugs that target angiogenesis may be a promising strategy for disease treatment. Isoimperatorin is a furanocoumarin with anti-inflammatory and anti-microbial effects. However, the impacts of isoimperatorin on angiogenesis and its underlying mechanisms remain unclear. This study aimed to verify its effects on vascular endothelial growth factor (VEGF)-induced endothelial angiogenesis...
February 16, 2024: Cardiovascular Drugs and Therapy
Hani Sabbour, Deepak L Bhatt, Yaser Elhenawi, Asma Aljaberi, Layal Bennani, Tarek Fiad, Khwaja Hasan, Shahrukh Hashmani, Rabih A Hijazi, Zafar Khan, Ronney Shantouf
PURPOSE: Patients with hyperlipidemia treated with statins remain at a residual cardiovascular (CV) risk. Omega-3 polyunsaturated fatty acids hold the potential to mitigate the residual CV risk in statin-treated patients, with persistently elevated triglyceride (TG) levels. METHOD: We reviewed the current evidence on the use of icosapent ethyl (IPE), an omega-3 fatty acid yielding a pure form of eicosapentaenoic acid. RESULTS: REDUCE-IT reported a significant 25% reduction in CV events, including the need for coronary revascularization, the risk of fatal/nonfatal myocardial infarction, stroke, hospitalization for unstable angina, and CV death in patients on IPE, unseen with other omega-3 fatty acids treatments...
February 16, 2024: Cardiovascular Drugs and Therapy
Ian S deSouza, Pragati Shrestha, Robert Allen, Jessica Koos, Henry Thode
PURPOSE: The available evidence to determine which antidysrhythmic drug is superior for pharmacologic cardioversion of recent-onset (onset within 48 h) atrial fibrillation (AF) is uncertain. We aimed to identify the safest and most effective agent for pharmacologic cardioversion of recent-onset AF in the emergency department. METHODS: We searched MEDLINE, Embase, and Web of Science from inception to February 21, 2023 (PROSPERO: CRD42018083781). Eligible studies were randomized controlled trials that enrolled adult participants with AF ≤ 48 h, compared a guideline-recommended antidysrhythmic drug with another antidysrhythmic drug or a different formulation of the same drug or placebo and reported specific adverse events...
February 7, 2024: Cardiovascular Drugs and Therapy
Qiuyu Xu, Gang Chen, Sanxi Ai, Ke Zheng, Bin Zhao, Xuemei Li
PURPOSE: Acute kidney injury (AKI) following anticoagulant application has received growing attention as a significant emerging complication of anticoagulation. Nevertheless, there remains a lack of real-world studies to compare the incidence, clinical features, and prognosis of AKI across different anticoagulant regimens. METHODS: Disproportionality analysis and Bayesian analysis were used to identify suspected AKI cases after different anticoagulant use within the Food and Drug Administration's Adverse Event Reporting System from January 2004 to March 2023...
February 6, 2024: Cardiovascular Drugs and Therapy
Spencer Ng, Kevin Friede, George A Stouffer
No abstract text is available yet for this article.
February 6, 2024: Cardiovascular Drugs and Therapy
Yanyan Ye, Fangyuan Chang, Yingchun Xu
No abstract text is available yet for this article.
January 31, 2024: Cardiovascular Drugs and Therapy
Mahsa Mansourian, Zahra Teimouri-Jervekani, Azam Soleimani, Rasool Nouri, Hamidreza Marateb, Marjan Mansourian
PURPOSE: Radiofrequency (RF) ablation is a prevalent treatment for atrial fibrillation (AF), targeting triggers within the pulmonary vein (PV) for elimination. This study evaluated heart rate variability (HRV) parameter changes at three intervals post-RF ablation: short-term (immediately to 1 month), medium-term (1 to 6 months), and long-term (6 months to 1 year). We compared two ablation techniques: circumferential PV isolation (CPVI) and segmental PV isolation (SPVI). METHODS: A thorough search of databases, including PubMed, Embase, Scopus, Web of Science, and Cochrane, in 2022 yielded 835 pertinent studies...
January 30, 2024: Cardiovascular Drugs and Therapy
Maurizio Giuseppe Abrignani, Edoardo Gronda, Marco Marini, Mauro Gori, Massimo Iacoviello, Pier Luigi Temporelli, Manuela Benvenuto, Giulio Binaghi, Arturo Cesaro, Alessandro Maloberti, Maria Denitza Tinti, Carmine Riccio, Furio Colivicchi, Massimo Grimaldi, Domenico Gabrielli, Fabrizio Oliva
Hyperkalaemia is one of the most common electrolyte disorders in patients with cardiovascular disease (CVD). The true burden of hyperkalaemia in the real-world setting can be difficult to assess, but in population-based cohort studies up to 4 in 10 patients developed hyperkalaemia. In addition to drugs interfering with potassium metabolism and food intake, several conditions can cause or worsen hyperkalaemia, such as advanced age, diabetes, and chronic kidney disease. Mortality, cardiovascular morbidity, and hospitalisation are higher in patients with hyperkalaemia...
January 30, 2024: Cardiovascular Drugs and Therapy
Kai-Yuan Chen, Zhou Liu, Jun-Hou Lu, Si-Yuan Yang, Xuan-Yi Hu, Gui-You Liang
Myocardial ischemia reperfusion injury (MIRI) represents a prevalent and severe cardiovascular condition that arises primarily after myocardial infarction recanalization, cardiopulmonary bypass surgery, and both stable and unstable angina pectoris. MIRI can induce malignant arrhythmias and heart failure, thereby increasing the morbidity and mortality rates associated with cardiovascular diseases. Hence, it is important to assess the potential pathological mechanisms of MIRI and develop effective treatments...
January 30, 2024: Cardiovascular Drugs and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.